Tumour copper levels regulate PD-L1 driven immune evasion

Download files
Access & Terms of Use
open access
Embargoed until 2022-01-01
Copyright: Voli, Florida
Altmetric
Abstract
Cancer immune evasion is recognised as a central hallmark of tumour development. One mechanism that cancer cells use to protect themselves from anti-tumour immune responses is the over-expression of Programmed Death Ligand 1 (PD-L1). The immune checkpoint protein Programmed Death receptor 1 (PD-1) expressed by lymphocytes negatively regulates T-cells effector functions against target cells, including tumour cells. Several therapeutic monoclonal antibodies targeting PD-L1/PD-1 have been approved by the FDA for adult melanoma and lung cancer. However, their efficacy is limited by acquired resistance and immune-related adverse events in many patients. Additionally, the regulation of PD-L1 expression on tumour cells is still poorly understood. Copper transporter 1 (CTR-1) and copper levels are elevated in tumours and the use of copper targeting agents is currently under intense investigations. It has been also reported that copper plays a major role in the immune system, but its activity is unclear. In this study, we demonstrated for the first time that copper plays a key role in the expression of PD-L1 in cancer cells. Tissue microarrays from neuroblastoma and glioblastoma patients showed a significant correlation between CTR-1 and PD-L1 expression (p<0.0001 and p=0.006 respectively). Deep analysis of the TCGA database showed that CTR-1 and PD-L1 association also occurs across many cancer types characterised by high copper levels, but not in the corresponding normal tissues. In vitro experiments showed that copper supplementation enhanced PD-L1 expression at mRNA and protein levels in cancer cells. Consistently, Dextran-Catechin (DC) and TEPA, copper-lowering drugs, were able to down-regulate PD-L1 expression in cancer cells, both post-transcriptionally by inhibiting EGFR-phosphorylation and promoting ubiquitin-mediated PD-L1 degradation and transcriptionally by reducing STAT signalling pathway. In vivo studies showed that copper-lowering drugs slowed tumour growth and improved mice survival, by down-regulating PD-L1 expression, which in turn caused a significantly increase in number of tumour-infiltrating CD8+ T cells and natural killer cells. This study reveals an important role for copper in regulating PD-L1 expression and it raises the potential of repurposing copper-lowering drugs to enhance immune checkpoint blockade. This novel therapeutic approach could target a wide spectrum of copper-dependent cancers.
Persistent link to this record
Link to Publisher Version
Link to Open Access Version
Additional Link
Author(s)
Voli, Florida
Supervisor(s)
Vittorio, Orazio
Kavallaris, Maria
Creator(s)
Editor(s)
Translator(s)
Curator(s)
Designer(s)
Arranger(s)
Composer(s)
Recordist(s)
Conference Proceedings Editor(s)
Other Contributor(s)
Corporate/Industry Contributor(s)
Publication Year
2019
Resource Type
Thesis
Degree Type
PhD Doctorate
UNSW Faculty
Files
download public version.pdf 4.71 MB Adobe Portable Document Format
Related dataset(s)